SEC Form 4 · accession 0001415889-18-001581
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alise Reicin
Officer — PRES., GLOBAL CLINICAL DEV.
Period of report
Nov 1, 2018
Accepted (ET)
Nov 2, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $75.61 | Nov 1, 2018 | A | 42,500 | A | — | Nov 1, 2028 | Common Stock | 42,500 | 42,500 | D |
| Restricted Stock UnitF5,F3,F4 | — | Nov 1, 2018 | A | 35,710 | A | — | — | Common Stock | 35,710 | 35,710 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest in four equal annual installments commencing on November 1, 2019.
- F2The option was issued pursuant to the Company's 2014 Equity Incentive Plan.
- F3Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F4The restricted stock units will vest in three equal annual installments commencing on November 1, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date.
- F5The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan.